Direct Cell-to-cell Transfer in Stressed Tumor Microenvironment Aggravates Tumorigenic or Metastatic Potential in Pancreatic Cancer
Overview
Authors
Affiliations
Pancreatic cancer exhibits a characteristic tumor microenvironment (TME) due to enhanced fibrosis and hypoxia and is particularly resistant to conventional chemotherapy. However, the molecular mechanisms underlying TME-associated treatment resistance in pancreatic cancer are not fully understood. Here, we developed an in vitro TME mimic system comprising pancreatic cancer cells, fibroblasts and immune cells, and a stress condition, including hypoxia and gemcitabine. Cells with high viability under stress showed evidence of increased direct cell-to-cell transfer of biomolecules. The resulting derivative cells (CD44/SLC16A1) were similar to cancer stem cell-like-cells (CSCs) with enhanced anchorage-independent growth or invasiveness and acquired metabolic reprogramming. Furthermore, CD24 was a determinant for transition between the tumorsphere formation or invasive properties. Pancreatic cancer patients with CD44/SLC16A1 expression exhibited better prognoses compared to other groups. Our results suggest that crosstalk via direct cell-to-cell transfer of cellular components foster chemotherapy-induced tumor evolution and that targeting of CD44 and MCT1(encoded by SLC16A1) may be useful strategy to prevent recurrence of gemcitabine-exposed pancreatic cancers.
Cell-cell fusion in cancer: The next cancer hallmark?.
Shultes P, Weaver D, Tadele D, Barker-Clarke R, Scott J Int J Biochem Cell Biol. 2024; 175():106649.
PMID: 39186970 PMC: 11752790. DOI: 10.1016/j.biocel.2024.106649.
Wu S, Yu W, Chien T, Ren Y, Chen C, Chiang C Cancer Cell Int. 2024; 24(1):35.
PMID: 38238749 PMC: 10795391. DOI: 10.1186/s12935-024-03213-8.
Deciphering cellular plasticity in pancreatic cancer for effective treatments.
Uddin M, Zhang D, Muqbil I, El-Rayes B, Chen H, Philip P Cancer Metastasis Rev. 2024; 43(1):393-408.
PMID: 38194153 DOI: 10.1007/s10555-023-10164-5.
Hioki K, Ryan D, Thesmar I, Lynch A, Pobezinsky L, Pobezinskaya E Front Immunol. 2024; 14:1272918.
PMID: 38179041 PMC: 10765531. DOI: 10.3389/fimmu.2023.1272918.
Ammar N, Hildebrandt M, Geismann C, Roder C, Gemoll T, Sebens S Antioxidants (Basel). 2023; 12(10).
PMID: 37891897 PMC: 10604597. DOI: 10.3390/antiox12101818.